Application of 3D Mass Spectrometry Imaging to TKIs

Lavinia Morosi, Silvia Giordano, Francesca Falcetta, Roberta Frapolli, Simonetta A. Licandro, Cristina Matteo, Massimo Zucchetti, Paolo Ubezio, Eugenio Erba, Sonja Visentin, Maurizio D'Incalci, Enrico Davoli

Research output: Contribution to journalArticle

Abstract

Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.

Original languageEnglish
Pages (from-to)748-751
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number5
DOIs
Publication statusPublished - Nov 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this